TY - JOUR
T1 - Diagnostic Utility of the Revised Lake Louise Criteria in Myocarditis Associated with Active Autoimmune Rheumatic Disease
AU - Hua, Alina
AU - Domenech-Ximenos, Blanca
AU - Begona Lopez, null
AU - Sanna, Giovanni
AU - Chiribiri, Amedeo
AU - Rajani, Ronak
AU - Marber, Michael
AU - D'Cruz, David
AU - Fernando, Michelle
AU - Ismail, Tevfik F
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/6/2
Y1 - 2025/6/2
N2 - Background: Cardiovascular magnetic resonance (CMR) is the principal non-invasive imaging modality used to diagnose idiopathic/viral myocarditis. The revised Lake Louise criteria (LLC) stipulate that a diagnosis can be made in the presence of one T1-based and one T2-based criterion. While the LLC have been extensively validated in viral myocarditis, their utility for the diagnosis of myocarditis due to an active autoimmune rheumatic disease is unknown. This study sought to assess the performance of the revised LLC in patients with clinically suspected myocarditis due to active systemic autoimmune disease. Methods: Patients with clinically active autoimmune rheumatic disease, symptoms of myocarditis, and elevated troponin levels were recruited and compared with controls with autoimmune rheumatic disease but no suspicion of autoimmune myocarditis. All patients underwent CMR at 1.5T including T1 and T2 mapping. Results: Thirty-seven patients with suspected myocarditis due to an active autoimmune rheumatic disease were recruited with a median (interquartile [IQR]) troponin level of 121 ng/L (72–318 ng/L). Overall, 65% (24/37) of patients met either of the two revised LLC resulting in a sensitivity (95% confidence interval) of 65% (49–78%) and specificity of 76% (57–89%). Only 32% (12/37) of patients fulfilled both of the main LLC (i.e., non-ischemic myocardial injury/edema with elevated T1 values or presence of late gadolinium enhancement and myocardial edema detected by increased T2 values or positive T2-STIR), resulting in a sensitivity of 32% (20–49%) and specificity of 100% (87–100%). Among controls, 24% (6/25) of patients had elevated native T1 values, but all had normal T2. Conclusion: In patients with suspected myocarditis due to autoimmune rheumatic disease, who are receiving immunosuppressive therapy, the LLC have a high specificity, but a lower sensitivity than in patients with viral myocarditis. Additional tests should therefore be used to improve disease detection in this population. Where the pre-test probability is high, in patients with suspected myocarditis due to autoimmune rheumatic disease who are undergoing immunosuppression, there may need to be greater reliance on one T1-based criterion rather than both LLC, with the recognition that there is an appreciable rate of raised T1 in controls without myocarditis.
AB - Background: Cardiovascular magnetic resonance (CMR) is the principal non-invasive imaging modality used to diagnose idiopathic/viral myocarditis. The revised Lake Louise criteria (LLC) stipulate that a diagnosis can be made in the presence of one T1-based and one T2-based criterion. While the LLC have been extensively validated in viral myocarditis, their utility for the diagnosis of myocarditis due to an active autoimmune rheumatic disease is unknown. This study sought to assess the performance of the revised LLC in patients with clinically suspected myocarditis due to active systemic autoimmune disease. Methods: Patients with clinically active autoimmune rheumatic disease, symptoms of myocarditis, and elevated troponin levels were recruited and compared with controls with autoimmune rheumatic disease but no suspicion of autoimmune myocarditis. All patients underwent CMR at 1.5T including T1 and T2 mapping. Results: Thirty-seven patients with suspected myocarditis due to an active autoimmune rheumatic disease were recruited with a median (interquartile [IQR]) troponin level of 121 ng/L (72–318 ng/L). Overall, 65% (24/37) of patients met either of the two revised LLC resulting in a sensitivity (95% confidence interval) of 65% (49–78%) and specificity of 76% (57–89%). Only 32% (12/37) of patients fulfilled both of the main LLC (i.e., non-ischemic myocardial injury/edema with elevated T1 values or presence of late gadolinium enhancement and myocardial edema detected by increased T2 values or positive T2-STIR), resulting in a sensitivity of 32% (20–49%) and specificity of 100% (87–100%). Among controls, 24% (6/25) of patients had elevated native T1 values, but all had normal T2. Conclusion: In patients with suspected myocarditis due to autoimmune rheumatic disease, who are receiving immunosuppressive therapy, the LLC have a high specificity, but a lower sensitivity than in patients with viral myocarditis. Additional tests should therefore be used to improve disease detection in this population. Where the pre-test probability is high, in patients with suspected myocarditis due to autoimmune rheumatic disease who are undergoing immunosuppression, there may need to be greater reliance on one T1-based criterion rather than both LLC, with the recognition that there is an appreciable rate of raised T1 in controls without myocarditis.
UR - http://www.scopus.com/inward/record.url?scp=105009514311&partnerID=8YFLogxK
U2 - 10.1016/j.jocmr.2025.101916
DO - 10.1016/j.jocmr.2025.101916
M3 - Article
C2 - 40467038
SN - 1097-6647
VL - 27
SP - 101916
JO - Journal of Cardiovascular Magnetic Resonance
JF - Journal of Cardiovascular Magnetic Resonance
IS - 2
M1 - 101916
ER -